{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:33:53Z","timestamp":1780090433464,"version":"3.54.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s10637-011-9640-6","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T17:42:18Z","timestamp":1299001338000},"page":"936-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model"],"prefix":"10.1007","volume":"30","author":[{"given":"Timothy P.","family":"Burkholder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Rempala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Knobeloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan A.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Barda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen L.","family":"Considine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Uhlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liandong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline K.","family":"Akunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis J.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Sanchez-Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Clawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Lahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"9640_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011\u20131027","journal-title":"J Clin Oncol"},{"key":"9640_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1042\/CS20040370","volume":"109","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109:227\u2013241","journal-title":"Clin Sci"},{"key":"9640_CR3","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"9640_CR4","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109","journal-title":"Cancer Res"},{"key":"9640_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 8:299\u2013309","journal-title":"Cancer Cell"},{"key":"9640_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242\u2013248","journal-title":"Nature"},{"key":"9640_CR7","unstructured":"Barda DA, Burkholder TP, Clayton JR, Hao Y, Henry JR, Knobeloch JM, McLean JA, Mendel D, Rempala ME, Wang ZQ, Yip YY, Zhong B (2010) U.S. Patent 7 666 879"},{"key":"9640_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.chembiol.2006.05.015","volume":"13","author":"B Okram","year":"2006","unstructured":"Okram B, Nagle A, Adrian FJ, Lee C, Ren P, Wang X, Sim T, Xie Y, Wang X, Xia G, Spraggon G, Warmuth M, Liu Y, Gray N (2006) A general strategy for creating \u201cinactive-conformation\u201d Abl inhibitors. Chem Biol 13:779\u2013786","journal-title":"Chem Biol"},{"key":"9640_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Sructural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938\u20131942","journal-title":"Science"},{"key":"9640_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbapap.2003.11.010","volume":"1697","author":"PW Manley","year":"2004","unstructured":"Manley PW, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W, Strauss A, Wood J (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 1697:17\u201327","journal-title":"Biochim Biophys Acta"},{"key":"9640_CR11","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1016\/j.bmcl.2005.05.096","volume":"15","author":"DM Sammond","year":"2005","unstructured":"Sammond DM, Nailor KE, Veal JM, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M (2005) Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorg Med Chem Lett 15:3519\u20133523","journal-title":"Bioorg Med Chem Lett"},{"key":"9640_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1021\/jm050786h","volume":"49","author":"FH Jung","year":"2006","unstructured":"Jung FH, Pasquet G, Lambert-van der Brempt C, Lohman JM, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S (2006) Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem 49:955\u2013970","journal-title":"J Med Chem"},{"key":"9640_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1087057107300221","volume":"12","author":"KL Huss","year":"2007","unstructured":"Huss KL, Blonigen PE, Campbell RM (2007) Development of a TranscreenerTM kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J Biomol Screen 12:578\u2013584","journal-title":"J Biomol Screen"},{"key":"9640_CR14","doi-asserted-by":"publisher","first-page":"19298","DOI":"10.1074\/jbc.M413059200","volume":"280","author":"X Wang","year":"2005","unstructured":"Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, Smallwood JE, Christe ME, Chatterjee A, Goodson T Jr, Vlahos CJ, Matter WF, Bloem LJ (2005) Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 280:19298\u201319305","journal-title":"J Biol Chem"},{"key":"9640_CR15","doi-asserted-by":"crossref","unstructured":"Hasumi Y, Babaa M, Ajimab R, Hasumi H, Valeraa VA, Kleina ME, Hainesc DC, Merinod MJ, Honga S-B, Yamaguchib TP, Schmidt LS, Linehana WM (2009) Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2 PNAS, 106: 18722\u201318727","DOI":"10.1073\/pnas.0908853106"},{"key":"9640_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1471-2164-9-264","volume":"9","author":"Y Chen","year":"2008","unstructured":"Chen Y, Wei T, Yan L, Lawrence L, Qian H-R, Burkholder TP, Starling JJ, Yingling JM, Shou J (2008) Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model. BMC Genomics 9:264","journal-title":"BMC Genomics"},{"key":"9640_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.1365-2141.2000.02317.x","volume":"111","author":"FM Abu-Ehuler","year":"2000","unstructured":"Abu-Ehuler FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br J Haematol 111:190\u2013195","journal-title":"Br J Haematol"},{"issue":"4","key":"9640_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/sj.leu.2401731","volume":"14","author":"WJ Rombouts","year":"2000","unstructured":"Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE (2000) (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14(4):675\u2013683","journal-title":"Leukemia"},{"key":"9640_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood.V97.1.89","volume":"97","author":"S Meshinchi","year":"2001","unstructured":"Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97:89\u201394","journal-title":"Blood"},{"key":"9640_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00277-009-0890-8","volume":"89","author":"EC Obermann","year":"2010","unstructured":"Obermann EC, Arber C, Jotterand M, Tichelli A, Hirschmann P, Tzankov A (2010) Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann Hematol 89:663\u2013669","journal-title":"Ann Hematol"},{"issue":"2","key":"9640_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/01926230600611836","volume":"34","author":"AP Hall","year":"2006","unstructured":"Hall AP, Westwood FR, Wadsworth PF (2006) Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 34(2):131\u20134","journal-title":"Toxicol Pathol"},{"key":"9640_CR22","unstructured":"Sutent (Sunitinib Malate) (2006) Pharmacology review, NDA Application No.: 021938 & 021968, Pfizer Inc"},{"key":"9640_CR23","unstructured":"Nexavar (Sorafenib Tosylate): Pharmacology Review, NDA Application No.: 021923, 2005. Bayer Pharmaceuticals Corporation"},{"key":"9640_CR24","unstructured":"Avastin (Bevacizumab): Pharmacology Review, BLA Application No.: 125085, 2004. Genetech, Inc"},{"issue":"2","key":"9640_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1124\/jpet.103.052530","volume":"307","author":"KG Moss","year":"2003","unstructured":"Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD (2003) Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307(2):476\u201380","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"9640_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491\u2013500","journal-title":"Lancet Oncol"},{"issue":"9362","key":"9640_CR27","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S0140-6736(03)12805-X","volume":"361","author":"C Robert","year":"2003","unstructured":"Robert C, Spatz A, Faivre S, Armand JP, Raymond E (2003) Tyrosine kinase inhibition and grey hair. Lancet 361(9362):1056","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1007\/s10637-011-9684-7","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T00:00:00Z","timestamp":1305849600000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-011-9640-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9640-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:24:15Z","timestamp":1678559055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-011-9640-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9640"],"URL":"https:\/\/doi.org\/10.1007\/s10637-011-9640-6","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s10637-011-9684-7","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,1]]},"assertion":[{"value":"17 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}